Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SABS 
SAB Biotherapeutics Inc (SABS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: SABS (1-star) is a SELL. SELL since 5 days. Simulated Profits (18.33%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.83
1 Year Target Price $8.83
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.38M USD | Price to earnings Ratio - | 1Y Target Price 8.83 |
Price to earnings Ratio - | 1Y Target Price 8.83 | ||
Volume (30-day avg) 5 | Beta 0.59 | 52 Weeks Range 1.00 - 4.99 | Updated Date 12/14/2025 |
52 Weeks Range 1.00 - 4.99 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16338.32% | Operating Margin (TTM) -37657.13% |
Management Effectiveness
Return on Assets (TTM) -22.76% | Return on Equity (TTM) 18.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 76688878 | Price to Sales(TTM) 1581.39 |
Enterprise Value 76688878 | Price to Sales(TTM) 1581.39 | ||
Enterprise Value to Revenue 1.21 | Enterprise Value to EBITDA 3.47 | Shares Outstanding 47606851 | Shares Floating 22589927 |
Shares Outstanding 47606851 | Shares Floating 22589927 | ||
Percent Insiders 12.37 | Percent Institutions 59.26 |
About SAB Biotherapeutics Inc
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-02-09 | Chairman & CEO Mr. Samuel J. Reich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.